Moderna Inc. (MRNA)
Moderna, Inc. (MRNA) UBS Global Healthcare Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) UBS Global Healthcare Conference November 13, 2024 6:30 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Eliana Merle Good afternoon, everyone. Thank you for joining us at the UBS Healthcare Conference.
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. "We are honored to be recognized by BioSpace as the most desirable large employer in the life sciences industry for the fourth year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna.
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Both stocks have made significant breakthroughs.
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna has received approval from Canada's health regulator for its respiratory syncytial virus vaccine in adults 60 years of age and older, the vaccine maker said on Friday.
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.1 "Today's approval is an example of how our mRNA platform can help address significant public health challenges like RSV," said Stéphane Bancel, Chief Executive Officer of Moderna. "As our second product approved by Health Canada, mRESVIA underscores our commitment to leveraging mRNA technology to protect vulnerable populations and contribute to a healthier future for Canadians.
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
Moderna Stock Rises on Surprise Q3 Profit
Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs.
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Call Start: 08:00 January 1, 0000 9:00 AM ET Moderna Inc. (NASDAQ:MRNA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 am ET Company Participants Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Eli Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Tyler Van Buren - TD Cowen Terence Flynn - Morgan Stanley Evan Wang - Guggenheim Edward Tenthoff - Piper Sandler Luca Issi - RBC Capital Courtney Breen - Bernstein Manos Mastorakis - Deutsche Bank Operator Good day and thank you for standing by. Welcome to the Moderna third quarter 2024 conference call.
2025 will be 'fairly challenging' for Moderna: Analyst
Moderna (MRNA) shares are getting a boost in Thursday's pre-market trading as the pharmaceutical giant reported an unexpected profit in its third quarter. The company posted $1.86 billion in revenue and adjusted earnings of $0.03 per share, while it was originally expecting a loss of about $1.90 per share, fueled by higher-than-expected sales of its COVID-19 vaccines.
Initial Claims Increased Slightly More Than Expected
The other long-expected big news item for market participants this week comes this afternoon, with the Federal Open Market Committee (FOMC) determining a new Fed funds rate. This follows the “red wave” election on Tuesday that still shows stock market indexes going higher after a gangbusters market Wednesday.
